A fresh drug target for multiple epithelial tumors discovered by Compugen Compugen Ltd.

CGEN-671, a fresh drug target for multiple epithelial tumors discovered by Compugen Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a fresh drug focus on for multiple epithelial tumors top-avana.com . CGEN-671 can be a membrane splice variant of CD55, a known drug focus on for gastric cancer that monoclonal antibody therapeutics are in medical development by others. The potential application of CGEN-671 as a drug focus on was predicted in primarily silico by Compugen through the use of its Monoclonal Antibody Targets Discovery Platform; the predicted molecule was after that validated experimentally in multiple epithelial tumors.